Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial
Authors:
- 25 October 2023
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 402 (10416) , 1979-1990
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trialThe Lancet, 2014
- Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With STEMI Undergoing Primary PCIJACC, 2014
- Outcomes With Various Drug-Eluting or Bare Metal Stents in Patients With ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 2013
- Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2013
- Do Differences in Repeat Revascularization Explain the Antianginal Benefits of Bypass Surgery Versus Percutaneous Coronary Intervention?Circulation: Cardiovascular Quality and Outcomes, 2012
- Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarctionEuropean Heart Journal, 2012
- Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug CoatingsCirculation, 2011
- Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction PatientsCirculation, 2008
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- A united interpretation of different uncertainty intervalsMeasurement, 2005